IP Library › Granted Patent US 6,933,116
Granted Patent B2
US 6,933,116 · App. 10/037,986 · Granted Aug 23, 2005

Nucleic acid ligand binding site identification

Assignee: Gilead Sciences, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,933,116
App. No.
10/037,986
Granted
Aug 23, 2005
Kind
B2
Abstract

This invention comprises nucleic acid ligand for use as a diagnostic reagent for detecting the presence or absence of a target molecule in a sample, and a diagnostic reagent to measure the amount of a target molecule in a sample. In a preferred embodiment the nucleic acid ligands are identified by the method of the invention referred to as the Systematic Evolution of Ligands by EXponential enrichment (SELEX), wherein a candidate mixture of nucleic acids are iteratively enriched in high affinity nucleic acids and amplified by further partitioning.

Claims (12)

1. A method for identifying a nucleic acid binding protein's binding site on a region of a DNA or RNA comprising:

a) providing a nucleic acid ligand to the nucleic acid binding protein wherein said ligand has a sequence and a structure selected from the group consisting of loops, stems, hairpins, pseudoknots, helices and bulges;

b) adding said nucleic acid ligand to said nucleic acid binding protein and said DNA or RNA region; and

c) determining whether said added nucleic acid ligand inhibits said protein from binding to said RNA or DNA region, whereby if the nucleic acid ligand is inhibitory, the sequence or structure of said inhibitory nucleic acid ligand assists in the identification of the binding site in the DNA or RNA region or its structure.

2. The method of claim 1 wherein said nucleic acid ligand is provided by the method comprising the steps of:

a) contacting a candidate mixture of nucleic acids each of which have a randomized sequence with the binding protein, whereby nucleic acids having an increased affinity to the protein relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby a nucleic acid ligand of the protein may be identified.

3. The method of claim 1 wherein the DNA or RNA region contains a site selected from the group consisting of a promoter, an origin of replication, a ribosomal binding site and a tRNA binding site.

4. The method of claim 1 wherein the protein regulates transcription.

5. The method of claim 1 wherein the protein regulates translation.

6. The method of claim 1 wherein the protein is selected from the group consisting of transcriptional activators, transcriptional repressors, transcription complexes at promoter sites, replication accessory proteins, DNA polymerases, RNA polymerases and translational repressors.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2002
From: NEXSTAR PHARMACEUTICALS, INC.
To: GILEAD SCIENCES, INC.
Reel/Frame 012872/0364 →
Continuity (9)
Continuation 0950234400 · Feb 10, 2000
Continuation 0914319000 · Aug 27, 1998
Continuation 0846960900 · Jun 6, 1995
Continuation 0842896400 · Apr 25, 1995
Continuation 0841211000 · Mar 27, 1995
Continuation 0840944200 · Mar 24, 1995
Continuation 0771413100 · Jun 10, 1991
Continuation 0753642800 · Jun 11, 1990
Related Publication 20030157487A1 · Aug 21, 2003